Sripal Bangalore, MD, MHA; Yu Guo, MA; Jinfeng Xu, PhD; et al.
free access
has audio
JAMA Cardiol. 2016;1(6):640-647. doi:10.1001/jamacardio.2016.0785
This study reports on rates of invasive treatment for cardiogenic shock before and after exclusion from public reporting in New York was implemented and compares these findings with rates in other states without public reporting.
-
Podcast:
Management of AMI With Cardiogenic Shock Before and After Exclusion From Reporting (JAMA Cardiology)
-
Editorial
The Complicated Calculus of Publicly Reporting Mortality After Percutaneous Coronary Intervention
Ajay J. Kirtane, MD, SM; Brahmajee K. Nallamothu, MD, MPH; Jeffrey W. Moses, MD
JAMA Cardiol
James M. McCabe, MD; Stephen W. Waldo, MD; Kevin F. Kennedy, MS; et al.
free access
JAMA Cardiol. 2016;1(6):648-654. doi:10.1001/jamacardio.2016.1806
This study examines the effects of a public reporting exclusion policy on the change on rates of revascularization and mortality for patients with acute myocardial infarction complicated by cardiogenic shock in New York vs comparative states without public reporting.
-
Editorial
The Complicated Calculus of Publicly Reporting Mortality After Percutaneous Coronary Intervention
Ajay J. Kirtane, MD, SM; Brahmajee K. Nallamothu, MD, MPH; Jeffrey W. Moses, MD
JAMA Cardiol
Jerome J. Federspiel, MD, PhD; Kevin J. Anstrom, PhD; Ying Xian, MD, PhD; et al.
free access
JAMA Cardiol. 2016;1(6):655-665. doi:10.1001/jamacardio.2016.1783
This study investigates changes in the findings of TRANSLATE-ACS, a cohort study comparing the safety and efficacy of prasugrel vs clopidogrel after PCI, when the study data are reanalyzed using instrumental variables vs the investigators鈥� original inverse probability treatment weighting approach.
-
Editorial
Randomization鈥擳here Is No Substitute
Gregg C. Fonarow, MD
JAMA Cardiol
Thomas A. Gaziano, MD, MSc; Gregg C. Fonarow, MD; Brian Claggett, PhD; et al.
free access
JAMA Cardiol. 2016;1(6):666-672. doi:10.1001/jamacardio.2016.1747
This 2-state Markov model estimates the cost-effectiveness of sacubitril/valsartan vs enalapril to treat patients with heart failure.
John H. Alexander, MD, MHS; Ulrika Andersson, MSc; Renato D. Lopes, MD, PhD, MHS; et al.
free access
JAMA Cardiol. 2016;1(6):673-681. doi:10.1001/jamacardio.2016.1829
This secondary analysis of a randomized clinical trial assesses the effects of apixaban doses in patients with atrial fibrillation and 1 dose-reduction criterion.
-
Editorial
Appropriate Apixaban Dosing: Prescribers Take Note
Jeffrey I. Weitz, MD; John W. Eikelboom, MBBS
JAMA Cardiol
Allan J. Walkey, MD, MSc; Emily K. Quinn, MS; Michael R. Winter, MPH; et al.
free access
JAMA Cardiol. 2016;1(6):682-690. doi:10.1001/jamacardio.2016.2181
This cohort study uses administrative claims data to describe use of anticoagulation for atrial fibrillation during sepsis and to compare risk of stroke and bleeding with vs without anticoagulation.
Jon White, PhD; Daniel I. Swerdlow, MD, PhD; David Preiss, PhD; et al.
free access
JAMA Cardiol. 2016;1(6):692-699. doi:10.1001/jamacardio.2016.1884
This study uses published GWAS data and mendelian randomization analysis to compare measures of association between lipid fractions (LDL, HDL, triglycerides) and coronary artery disease vs diabetes.
Jerry C. Lee, MS, MPhil; Tomasz Zdrojewski, MD, PhD; Michael J. Pencina, PhD; et al.
free access
JAMA Cardiol. 2016;1(6):700-707. doi:10.1001/jamacardio.2016.1585
This analysis of 2 population-based surveys examines the differences in recommendations regarding statin therapy between the American College of Cardiology/American Heart Association guidelines for the management of cholesterol and the European Society of Cardiology/European Atherosclerosis Society guidelines.